** Shares of Immuron IMC.AX surge as much as 27% to
A$0.094, their biggest intraday jump since May 9
** The biopharmaceutical firm receives Good Manufacturing
Practice clearance from Therapeutic Goods Administration (TGA)
to release and dispatch Travelan, an oral immunotherapeutic drug
for treatment of travellers' diarrhoea, to customers this week
** "Immuron's resolution of supply and stock outages will
allow continuation of anticipated growth in sales in Australia,"
says co
** Stock hits highest level since May 15
** More than 746,000 shares have changed hands, compared
with the 30-day average of about 198,000 shares
** As of last close, stock down ~14% YTD
(Reporting by Upasana Singh in Bengaluru)
((Upasana.Singh@thomsonreuters.com))